NL-1

188532-26-5

335.46

DMSO : 250 mg/mL (745.25 mM; Need ultrasonic)

Autophagy; Metabolic Enzyme/Protease

NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC₅₀s of 47.35 uM and 56.26 uM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway^[1]. IC50 & Target: MitoNEET^[1] In Vitro: NL-1 (10-100 uM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC₅₀s of 29.48 uM, 94.26 uM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC₅₀ values of around 60 uM for NL-1^[1].
NL-1 (60 uM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death^[1].
NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells^[1]. In Vivo: NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model^[1].